Business Context and Reporting Period
This Form 8-K was filed by Gain Therapeutics, Inc. (GANX) on October 21, 2024. The report addresses a regulatory event concerning the company's listing status on The Nasdaq Global Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only quantitative value disclosed is the regulatory threshold for the Market Value of Listed Securities (MVLS), which is $50 million.
Material Changes
The primary material change reported is the resolution of a listing deficiency. On July 11, 2024, the company received notice of non-compliance with Nasdaq Listing Rule 5450(b)(2)(A) because its MVLS fell below $50 million for 30 consecutive business days. On October 21, 2024, Nasdaq staff determined that the company has regained compliance with the $50 million MVLS requirement, closing the matter.
Guidance, Outlook, and Risks
The filing confirms that the company is now in compliance with all Nasdaq Global Market listing requirements. No forward-looking guidance, management commentary on operations, or new risk factors were disclosed in this specific report. The company previously had until January 7, 2025, to regain compliance, but achieved it ahead of that deadline.
Investor Verification Checklist
- Verify the current market capitalization of Gain Therapeutics, Inc. to ensure it remains above the $50 million threshold.
- Review the July 12, 2024 Form 8-K for details on the initial non-compliance notice.
- Confirm the company's continued status as an emerging growth company.
- Monitor future filings for any recurrence of listing deficiency notices.